Therapeutic Effects of Newly Synthesized Boron Compounds (BGM and BGD) on Hepatocellular Carcinoma

Biol Trace Elem Res. 2022 Jan;200(1):134-146. doi: 10.1007/s12011-021-02647-9. Epub 2021 Feb 26.

Abstract

Boron has an important potential for facilitating biological activity and for use in pharmaceutical drug design. Boron glycine monoester (BGM) and boron glycine diester (BGD) compounds containing boron atoms were synthesized and investigated their cytotoxic, oxidative stress, and antimicrobial activities on the HepG2 cancer cell line. The cytotoxic activity of newly synthesized boron compounds on hepatocellular carcinoma was determined by the MTT method for 48 h. Antioxidant (CAT, GSH), lipid peroxidation (MDA), and enzyme activity (ACP, ALP) analyses were determined by spectrophotometric methods in HepG2 cells. Antimicrobial activity was determined by the disk diffusion method. After 48 h of BGM and BGD application to HepG2 cells, we found the IC50 values as 9.9 mM and 24 mM, respectively. While CAT and ACP enzyme activities decreased in all groups compared to the control, ALP enzyme activity did not change in the BGM group but increased in the BGD group. It was determined that the GSH level did not change in all groups, while the MDA level increased. It has been stated that these IC50 doses of BGM and BGD have antibacterial effects on Staphylococcus aureus ATCC 29213 and Escherichia coli ATCC 25922. Newly synthesized boron compounds, particularly BGM, with their cytotoxic, oxidative stress, and antimicrobial effects, could provide a new therapeutic approach for the treatment of hepatocellular carcinoma.

Keywords: Antimicrobial; Boron glycine diester; Boron glycine monoester; HepG2; Oxidative stress.

MeSH terms

  • Antioxidants
  • Boron / pharmacology
  • Boron Compounds / pharmacology
  • Carcinoma, Hepatocellular* / drug therapy
  • Glycine
  • Humans
  • Liver Neoplasms* / drug therapy

Substances

  • Antioxidants
  • Boron Compounds
  • Boron
  • Glycine

Grants and funding